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The invention described herein is directed to the use of 
acetyl L - carnitine , or propionyl L - carnitine , or a salt thereof , 
for preparing a medicament for increasing neurogenesis in 
neural tissue ; in which said increased neurogenesis is useful 
for preventing central nervous system disorders due to 
ageing or genetic predisposition . 
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FIGURE 1 




ALC- acetyl L - carnitine ; VPA- valproic acid . 
Mean #SD ( n - 3 exp , in triplicates ) . 
Student's test ; * p < 0.05 ; ** p < 0.01 ; *** p < 0.001 ; vs vehicle . 
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FIGURE 2 
MAP2 - positive cells ( new neurons ) , nuclei are counterstained with Draq5 
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FIGURE 3 
% of apoptosis after ALC ( acetyl L - carnitine ) and VPA ( valproic acidl 
incubation 
* apoptoticfucle 4 
300UN ALCAR 
ALCAR = acetyl L - carnitine . 
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FIGURE 4 
% of necrosis after ALC ( 100 UM ; 300 UM ; and 1 mm ) and VPA incubation 
2.500 
LOH activity(Abs490m) 1 
1000M ALCAR 
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FIGURE 5 
Specific effect of ALC on cells at various stages of differentiation 
X vai viable cells 
progenitor cells ( MAP2 Anesti ) 




Ons 300 x 303 
Synonymous : acetyl L - carnitine = ALC = ALCAR = L - acet . 
Mean . SD ( n = 3 exp , in triplicates ) . 
Student's- test ; * p < 0,05 ; ** p < 0.01 ; *** p < 0.001 ; vs vehicle . 
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FIGURE 6 
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COMPOUNDS USEFUL FOR INCREASING 
NEUROGENESIS IN NEURAL TISSUE 
FIELD OF THE INVENTION 
[ 0001 ] The present invention relates to the use of alkanoyl 
L - carnitines for increasing neurogenesis . 
[ 0002 ] In particular , the present invention relates to the use 
of acetyl L - carnitine or propionyl L - carnitine or a salt 
thereof , for increasing neurogenesis . 
BACKGROUND OF THE INVENTION 
[ 0003 ] Neurogenesis , or the birth of new neuronal cells , 
was thought to occur only in developing organisms . How 
ever , recent research has demonstrated that neurogenesis 
docs indeed continue into and throughout adult life in both 
vertebrate and invertebrate organisms . Neural stem cells 
( NSC ) are a source for new neurons in the mammalian 
central nervous system ( CNS ) . NSC are located within the 
ependymal and / or subventricular zone ( SVZ ) lining the 
lateral ventricle ( Cell 1999 ; 97 : 703-716 ; Cell 1999 ; 96 : 25 
34 ) and in the dentate gyrus of the hippocampal formation 
( J. Neurobiol . 1998 ; 36 : 249-266 ) . Studies have revealed the 
potential for several additional locations of NSC within the 
adult CNS ( J. Neurosci . 1999 ; 19 : 8487-8497 ) . Asymmetric 
division of NSC maintains their starting number , while 
generating a population of rapidly dividing precursor , or 
progenitor cells ( Cell 1999 ; 96 : 25-34 ) . The progenitor cells 
respond to a range of cues that dictate the extent of their 
proliferation and their fate , both in terms of differentiation 
and positioning . 
[ 0004 ] The NSC of the ventricular system in the adult are 
likely counterparts of the embryonic ventricular zone stem 
cells lining the neural tube . The progeny of these embryonic 
cells migrate away to form the CNS as differentiated neurons 
and glia ( Developmental Neurobiology . 1991 ; pp 401-451 ) . 
NSC persist in the adult lateral ventricle wall ( LVW ) , 
generating neuronal progenitors that migrate down the ros 
tral migratory stream to the olfactory bulb . There , they 
differentiate into granule cells and periglomerular neurons 
( Proc . Natl . Acad . Sci . USA 1993 ; 90 : 2074-2077 ) . Substan 
tial neuronal death occurs in the olfactory bulb , creating a 
need for continuous replacement of lost neurons which is 
satisfied by the migrating progenitors derived from the LVW 
( Neurosci . Lett . 2000 ; 291 : 17-20 ) . In addition , there are 
indications that lost neurons from other brain regions can be 
replaced by progenitors from the LVW that differentiate into 
the phenotype of the lost neurons with appropriate neuronal 
projections and synapses with the correct target cell type 
( Proc . Natl . Acad . Sci . USA 1997 ; 94 : 11663-11668 ; Nature 
2000 ; 405 : 951-955 ) . 
[ 0005 ] In vitro cultivation techniques have been estab 
lished to identify the external signals involved in the regu 
lation of NSC proliferation and differentiation ( Cell 1999 ; 
96 : 25-34 ; Exp . Cell Res . 1999 ; 253 : 733-736 ) . The mitogens 
EGF and basic FGF allow cell culture expansion of neural 
progenitors isolated from the ventricle wall and the hip 
pocampus ( Science 1997 ; 276 : 66-71 ; Exp . Cell Res . 1999 ; 
253 : 733-736 ) . These dividing progenitors remain in an 
undifferentiated state , and grow into large clones of cells 
known as neurospheres . Upon the withdrawal of the mito 
gens and the addition of serum , the progenitors differentiate 
into neurons , astrocytes and oligodendrocytes , which are the 
three cell lineages of the brain ( Cell 1999 ; 97 : 703-716 ; Cell 
1999 ; 96 : 25-34 ) . Specific growth factors can be added to 
alter the proportions of each cell type formed . For example , 
CNTF acts to direct the neural progenitors to an astrocytic 
fate ( Genes Dev . 1996 ; 10 : 3129-3140 ; J. Neurosci . 1998 ; 
18 : 3620-3629 ) . The thyroid hormone , triiodothyronine ( T3 ) , 
promotes oligodendrocyte differentiation ( Genes Dev . 1996 ; 
10 : 3129-3140 ) , while PDGF enhances neuronal differentia 
tion by progenitor cells ( Genes Dev . 1996 ; 10 : 3129-3140 ; 
Neuron 1997 ; 18 : 553-562 ) . Recently , it has been shown that 
indeed adult regenerated neurons are integrated into the 
existing brain circuitry , and contribute to ameliorating neu 
rological deficits ( Cell 2002 ; 110 : 429441 ) . Interestingly , 
observations have also shown that neurogenesis is occurring 
not only at the level of the olfactory bulb and hippocampus . 
In this respect it has been suggested that this process can also 
occur in the adult mouse substantia nigra , opening up a new 
field of investigation for the treatment of Parkinson s disease 
( Proc . Natl . Acad . Sci . USA 2003 ; 100 : 7925-7930 ) . 
[ 0006 ] The ability to expand neural progenitors and 
manipulate their cell fate has enormous implications for 
transplant therapies for neurological diseases where specific 
cell types are lost . Parkinson's disease ( PD ) , for example , is 
characterized by degeneration of dopaminergic neurons in 
the substantia nigra . Previous transplantation treatments for 
PD patients have used fetal tissue taken from the ventral 
midbrain at a time when substantia nigra dopaminergic 
neurons are undergoing terminal differentiation ( Prog . Neu 
robiol . 1994 ; 44 : 1-35 ) . These cells have been grafted onto 
the striatum where they form synaptic contacts with host 
striatal neurons , their normal synaptic target . This restores 
dopamine turnover and release to normal levels with sig 
nificant functional benefits to the patient . ( Prog . Neurobiol . 
1994 ; 44 : 1-35 ) . However , the grafting of fetal tissue is 
limited by ethical considerations and a lack of donor tissue . 
The expansion and manipulation of adult NSC can poten 
tially provide a range of well characterized cells for trans 
plant - based strategies for neurodegenerative disease such as 
PD . To this aim , the identification of factors and pathways 
that govern the proliferation and differentiation of neural cell 
types is fundamentally important . 
[ 0007 ] Studies have shown that intraventricular infusion 
of both EGF and basic FGF induces proliferation in the adult 
ventricle wall cell population . In the case of EGF , extensive 
migration of progenitors into the neighboring striatal paren 
chyma has been observed ( J. Neurosci 1996 ; 16 : 2649-2658 ; 
J. Neurosci 1997 ; 17 : 5820-5829 ) . EGF increases differen 
tiation into glial lineage and reduced the generation of 
neurons ( J. Neurosci 1997 ; 17 : 5820-5829 ) . Additionally , 
intraventricular infusion of BDNF in adult rats increases the 
number of newly generated neurons in the olfactory bulb 
and rostral migratory stream , and in parenchymal structures , 
including the striatum , septum , thalamus and hypothalamus 
( J. Neurosci . 2001 ; 21 : 6706-6717 ) . Thus , several studies 
have shown that the proliferation of progenitors within the 
SVZ of the LVWcan be stimulated and that their lineage can 
be guided to neuronal or glial fates . Yet , the number of 
factors known to affect neurogenesis in vivo is small and 
their effects are adverse or limited . 
[ 0008 ] As mentioned above , the identification of factors 
and pathways that govern the proliferation and differentia 
tion of neural cell types is fundamentally important in the 
medical field . 
[ 0009 ] The use of acetyl L - carnitine or propionyl L - car 
nitine in the medical field are already known . 
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[ 0010 ] U.S. Pat . No. 4,346,107 relates to the use of acetyl 
L - carnitine for the therapeutical treatment of patients with 
impaired cerebral metabolism , as for instance in the states of 
senile and presenile psychomotor involution and in senile 
and presenile dementia . 
[ 0011 ] U.S. Pat . No. 4,343,816 relates to the use of acetyl 
L - carnitine for the therapeutical treatment of patients with 
peripheral vascular diseases such as typically , Raynaud's 
disease . 
[ 0012 ] WO 9857629 relates to the use of acetyl L - carni 
tine for the therapeutical treatment of young individuals 
suffering from mood disorders classifiable as dysthymia 
( DMS IV ) and a depressive , irritable , cyclothymic person 
ality or temperament on the basis of DMS IV and AXIS II 
classifications , involving definite abuse of psychotropic sub 
stances . 
[ 0013 ] WO 03066041 relates to the use of acetyl L - car 
nitine for the therapeutical treatment of depression in non 
demented geriatric subjects having major depressive disor 
der ( NDG - MDD ) . 
[ 0014 ] EP 0256999 relates to the use of acetyl L - carnitine 
for the therapeutical treatment of patients affected by acute 
or chronic peripheral neuropathy . 
[ 0015 ] EP 0498144 relates to the use of acetyl L - carnitine 
for the therapeutical treatment of traumatic coma . In this 
publication is also reported that acetyl L - carnitine is able to 
increase the cerebral blood flow ( CBF ) measured by means 
of SPECT ( Single - Photon Emission Computed Tomogra 
phy ) . 
[ 0016 ] EP 0793962 the use of propionyl L - carnitine for 
treating chronic arteriosclerosis obliterans in patients with 
severely disabling intermittent claudication . 
[ 0017 ] It has been well established that new neurons are generated in the adult hippocampus throughout life by 
neural stem / progenitor cells ( NSC ) . Neurogenesis is a 
regenerative process responsive to external stimuli , involved 
in learning , memory and mood regulation . Neurogenesis is 
therefore believed to be an important form of neural regen 
eration , enabling organisms to adapt to environmental 
changes throughout life . 
[ 0018 ] The rate of hippocampal neurogenesis significantly 
changes on physiological or pathological influences , such as 
physical activity , environmental enrichment , stress , mood 
disorders , ageing and neurodegenerative disorders . Indeed , 
during ageing , there is an age - related decline in adult 
neurogenesis . This decline is mostly related to decreased 
proliferation , associated to decreased stimulation to prolif 
erate in an ageing brain . Natural or stimulated hippocampal 
neurogenesis play an important role in the clinical effects of 
antidepressants and possibly reduced neurogenesis may be 
involved in brain areas ( including hippocampus ) atrophy 
associated with depression . In Alzheimer's Disease ( AD ) , 
there is also evidence for decreased neurogenesis , that 
accompanies the neuronal loss characteristic of the disease . 
[ 0019 ] In the medical field is felt a perceived need to have 
available new compound , or a new use of known compound , 
useful for stimulating neurogenesis for the prevention of 
neuronal loss in normal or pathological processes in the 
brain . 
fact , ALC has a marked concentration - dependent hippocam 
pal neurogenic activity as demonstrated by the increase in 
the percentage of MAP - 2 positive cells ( i.e. new neurons ) in 
culture . 
[ 0021 ] FIG . 2 shows the hippocampal neurogenic activity 
of ALC ( MAP2 - positive cells evaluated by MAP - 2 staining 
in cultured neurons by immunofluorescence staining . Nuclei 
were stained with Draq5 . 
[ 0022 ] FIGS . 3 and 4 describe that the neurogenic activity 
of ALC is not correlated to neuroprotective activity . In fact , 
at the concentrations that induced neurogenesis , ALC ( 100 
uM ; 300 uM or 1 mM ) did not reduce the percentage of 
apoptotic nuclei ( FIG . 3 ) or even the activity of the LDH 
enzyme , an index of necrosis ( FIG . 4 ) . 
[ 0023 ] In FIG . 5 is shown the specific effect of ALC on 
cells at various stages of differentiation . In order to better 
understand FIG . 5 it is important to clarify that “ Nestin ” , an 
intermediate filament protein predominantly expressed by 
neural stem cells was used as a specific marker In fact , only 
nestin - positive ( nestint ) cells form spheres when placed in 
the culture conditions used for neural stem cells . In particu 
lar , mature neurons are positive for MAP2 and negative for 
nestin , immature neurons are positive for both MAP2 and 
nestin , stem progenitor cells are negative for MAP2 and 
positive for nestin , progenitor cells are negative for both 
MAP2 and nestin ( see FIG . 5 ) . 
[ 0024 ] In FIG . 6 is shown that PLC and ALC are activator 
of NPC neuronal differentiation . In fact PLC increased the 
number of both mature neurons and immature neurons and 
reduced the number of a subpopulation of undifferentiated 
stem / neural progenitors , although in a lesser extent com 
pared to ALC . On the contrary , LC had no effect . 
[ 0025 ] Moreover the results demonstrated that ALC and 
PLC effects on NPC differentiation were not due to neuro 
protective effects on newly generated immature or mature 
neurons . 
[ 0026 ] ( Synonymous : acetyl 
L - carnitine = ALC = ALCAR = L - acet ; propionyl L - carnitine 
= PLC = L - Prop ; LC = L - carnitine = L - car ) . 
DESCRIPTION OF THE INVENTION 
[ 0027 ] The present invention relates to an alkanoyl L - car 
nitine , or a salt thereof , for use for increasing neurogenesis 
in neural tissue . 
[ 0028 ] It is therefore an object of the present invention 
acetyl L - carnitine or propionyl L - carnitine or a salt thereof , 
for use for increasing neurogenesis in neural tissue . 
[ 0029 ] It is a further object of the present invention acetyl 
L - carnitine or propionyl L - carnitine , for use as a medica 
ment or a food supplement for increasing neurogenesis in 
neural tissue ; in which said increased neurogenesis is useful 
for preventing central nervous system disorders . 
( 0030 ] It is a further object of the present invention acetyl 
L - carnitine or propionyl L - carnitine , for use as a medica 
ment or a food supplement for increasing neurogenesis in 
neural tissue ; in which said increased neurogenesis is useful 
for preventing central nervous system disorders due to 
ageing or genetic predisposition . 
[ 0031 ] It is a further object of the present invention acetyl 
L - carnitine or propionyl L - carnitine , for use as a medica 
ment or a food supplement for the prevention of diseases or 
disturbances of the central nervous system , in which said 
diseases or disturbances are caused by the loss of neurons 
due to age or genetic predisposition . 
DESCRIPTION OF THE FIGURES 
[ 0020 ] FIG . 1 describes that ALC has a concentration 
dependent strengthening effect on the differentiation of stem 
cells / adult progenitors to mature and immature neurons . In 
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[ 0032 ] It is a further object of the present invention acetyl 
L - carnitine or propionyl L - carnitine , for use as a medica 
ment or a food supplement for the prevention of diseases or 
disturbances of the central nervous system , in which said 
diseases or disturbances respond to an increased neurogen 
esis . 
[ 0033 ] It is a further object of the present invention the use 
of acetyl L - carnitine or propionyl L - carnitine , or a salt 
thereof , for preparing a medicament or a food supplement 
for increasing neurogenesis in neural tissue ; in which said 
increased neurogenesis is useful for preventing central ner 
vous system disorders . 
[ 0034 ] It is a further object of the present invention the use 
of acetyl L - carnitine or propionyl L - carnitine , or a salt 
thereof , for preparing a medicament or a food supplement 
for increasing neurogenesis in neural tissue ; in which said 
increased neurogenesis is useful for preventing central ner 
vous system disorders due to ageing or genetic predisposi 
tion . 
[ 0035 ] It is a further object of the present invention the use 
of acetyl L - carnitine or propionyl L - carnitine , for preparing 
a medicament or a food supplement for the prevention of 
diseases or disturbances of the central nervous system , in 
which said diseases or disturbances are caused by the loss of 
neurons due to age or genetic predisposition . 
[ 0036 ] It is a further object of the present invention the use 
of acetyl L - carnitine or propionyl L - carnitine , for preparing 
a medicament or a food supplement for the prevention of 
diseases or disturbances of the central nervous system , in 
which said diseases or disturbances respond to an increased 
neurogenesis . 
[ 0037 ] It is a further object of the present invention a 
method for preventing central nervous system disorders , by 
administering to a patient in need thereof an amount of 
acetyl L - carnitine or propionyl L - carnitine , suitable for 
increasing neurogenesis . 
[ 0038 ] It is a further object of the present invention a 
method for preventing central nervous system disorders due 
to ageing or genetic predisposition , by administering to a 
patient in need thereof an amount of acetyl L - carnitine or 
propionyl L - carnitine , suitable for increasing neurogenesis . 
[ 0039 ] It is a further object of the present invention a 
method for increasing neurogenesis , by administering to a 
patient in need thereof a suitable amount of acetyl L - carni 
tine or propionyl L - carnitine , for preventing central nervous 
system disorders . 
[ 0040 ] It is a further object of the present invention a 
method for increasing neurogenesis by administering to a 
patient in need thereof a suitable amount of acetyl L - carni 
tine or propionyl L - carnitine , for preventing central nervous 
system disorders due to ageing or genetic predisposition . 
[ 0041 ] It is a further object of the present invention a 
method for increasing neurogenesis , in which said increased 
neurogenesis is useful for preventing central nervous system 
disorders , by chronically administering to a patient in need 
thereof a suitable amount of acetyl L - carnitine or propionyl 
L - carnitine . 
[ 0042 ] It is a further object of the present invention a 
method for increasing neurogenesis , in which said increased 
neurogenesis is useful for preventing central nervous system 
disorders due to ageing or genetic predisposition , by chroni 
cally administering to a patient in need thereof a suitable 
amount of acetyl L - carnitine or propionyl L - carnitine . 
[ 0043 ] The diseases or disturbances due to genetic predis 
position and / or linked to ageing , that can be prevented 
according to the present invention are selected from the 
group consisting of : neurodegenerative disorders , Parkin 
son's disease and Parkinsonian disorders , Huntington's dis 
ease , Alzheimer's disease , multiple sclerosis , amyotrophic 
lateral sclerosis , Shy - Drager syndrome , Lewy body disease , 
spinal ischemia , ischemic stroke , cerebral infarction , geri 
atric dementia , other cognitive impairments and depression . 
[ 0044 ] It is evident that according to the present invention 
are not included patients who have traumatic disturbances of 
the nerves ( for example injured nerves ) or of the CNS ( for 
example traumatic coma ) . 
[ 0045 ] “ Neurogenesis " is defined herein as proliferation , 
differentiation , migration , or survival of a neural cell in vivo 
or in vitro . In a preferred embodiment , the neural cell is an 
adult , fetal , or embryonic neural stem cell or progenitor cell . 
Neurogenesis also refers to a net increase in cell number or 
a net increase in cell survival . As used herein , " NSC ” would 
include , at least , all brain stem cells , all brain progenitor 
cells , and all brain precursor cells . 
[ 0046 ] In this disclosure , the terms disease or disorder 
shall have the same meaning . 
[ 0047 ] The administration of acetyl L - carnitine or propio 
nyl L - carnitine , may be systemic or direct into the CNS of 
a patient . Routes of administration include oral , subcutane 
ous , transdermal , intraperitoneal , intramuscular , in vein , 
intracerebroventricular , intraparenchymal , intrathecal , 
intracranial , buccal , mucosal , nasal , pulmonary , and rectal 
administration or administration by a liposome delivery 
system . 
[ 0048 ] Preferably , the pharmaceutical composition is used 
to prevent diseases by stimulating neurogenesis ( i.e. , cell 
growth , proliferation , migration , survival and / or differentia 
tion ) . For prevention , a method of the invention comprises 
administering to the subject an effective amount of a phar 
maceutical composition including acetyl L - carnitine , or pro 
pionyl L - carnitine , in a dosage range of 0.1 g / day to 4.00 
g / day ; preferably in a dosage range of 1 to 2.00 g / day ; most 
preferably 1.5 g / day in a single or multiple dose . 
[ 0049 ] The composition of the invention may further 
comprise physiologically acceptable carriers . 
[ 0050 ] According to the present invention physiologically 
acceptable carriers may be any carrier known in the field as 
suitable for pharmaceutical ( i.e. , topical , oral , and parent 
eral ) application . Suitable pharmaceutical carriers and for 
mulations are described , for example , in Remington's Phar 
maceutical Sciences ( 19th ed . ) ( Genarro , ed . ( 1995 ) Mack 
Publishing Co. , Easton , Pa . ) . 
[ 0051 ] Any of the methods of the invention may be used 
to prevent a symptom of a neurological disease or disorder 
such as Parkinson's disease ( shaking palsy ) , including pri 
mary Parkinson's disease , secondary parkinsonism , and 
postencephalitic parkinsonism ; drug - induced movement 
disorders , including parkinsonism , acute dystonia , tardive 
dyskinesia , and neuroleptic malignant syndrome ; Hunting 
ton's disease ( Huntington's chorea ; chronic progressive 
chorea ; hereditary chorea ) ; delirium ( acute confusional 
state ) ; dementia ; Alzheimer's disease ; non Alzheimer's 
dementias , including Lewy body dementia , vascular demen 
tia , Binswanger's dementia ( subcortical arteriosclerotic 
encephalopathy ) , dementia pugilistica , normal - pressure 
hydrocephalus , general paresis , frontotemporal dementia , 
multi - infarct dementia , and AIDS dementia ; age - associated 
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memory impairment ( AAMI ) ; amnesias , such as retrograde , 
anterograde , global , modality specific , transient , stable , and 
progressive amnesias , and Korsakoffs disease . 
[ 0052 ] Other diseases and disorders include idiopathic 
orthostatic hypotension , Shy - Drager syndrome , progressive 
supranuclear palsy ( Steele - Richardson - Olszewski syn 
drome ) ; structural lesions of the cerebellum , such as those 
associated with infarcts , hemorrhages , or tumors ; spinocer 
ebellar degenerations such as those associated with Friedre 
ich's ataxia , abetalipoproteinemia ( e.g. , Bassen - Kornzweig 
syndrome , vitamin E deficiency ) , Refsum's disease ( phy 
tanic acid storage disease ) , cerebellar ataxias , multiple sys 
tems atrophy ( olivopontocerebellar atrophy ) , ataxia - telangi 
ectasia , and mitochondrial multisystem disorders ; acute 
disseminated encephalomyelitis ( postinfectious encephalo 
myelitis ) ; adrenoleukodystrophy and adrenomyeloneuropa 
thy ; Leber's hereditary optic atrophy ; HTLV - associated 
myelopathy ; and multiple sclerosis ; motor neuron disorders 
such as amyotrophic lateral sclerosis , progressive bulbar 
palsy , progressive muscular atrophy , primary lateral sclero 
sis and progressive pseudobulbar palsy , and spinal muscular 
atrophies such as type I spinal muscular atrophy ( Werdnig 
Hoffman disease ) , type II ( intermediate ) spinal muscular 
atrophy , type III spinal muscular atrophy ( Wohlfart - Kugel 
berg - Welander disease ) , and type IV spinal muscular atro 
phy . 
[ 0053 ] The methods of the invention can be used to treat 
any mammal , including humans , cows , horses , dogs , sheep , 
and cats . Preferably , the methods of the invention are used 
to treat humans . In one aspect , the invention provides a 
regenerative prevention for neurological disorders by stimu 
lating cells ( e.g. , stem cells ) to grow , proliferate , migrate , 
survive , and / or differentiate to replace neural cells that have 
been lost or destroyed . In vivo stimulation of such cells ( e.g. , 
stem cells ) can be accomplished by locally administering 
( via any route ) the neurogenesis modulating agent of the 
invention to the cells in an appropriate formulation . 
[ 0054 ] Pharmaceutical compositions suitable for use in the 
present invention include compositions wherein the active 
ingredients are contained in an effective amount to achieve 
its intended purpose . More specifically , a therapeutically 
effective amount means an amount effective to optimally 
stimulate ( e.g. , stem cell or progenitor cell ) proliferation . It 
will be appreciated that the unit content of active ingredient 
or ingredients contained in an individual dose of each 
dosage form need not in itself constitute an effective amount 
since the necessary effective amount can be reached by 
administration of a plurality of dosage units ( such as cap 
sules or tablets or combinations thereof ) . In addition , it is 
understood that at some dosage levels , an effective amount 
may not show any measurable effect ( the measurable effect 
could be lack of deterioration ) until after a week , a month , 
three months , six months or a year or more of usage . 
Determination of the effective amounts is well within the 
capability of those skilled in the art . The specific dose level 
for any particular user will depend upon a variety of factors 
including the age , the physical activity level , general health , 
and the severity of the disorder to be prevented . 
[ 0055 ] For any compound , the therapeutically effective 
dose can be estimated initially either in cell culture assays or 
in animal models , usually mice or rats . 
[ 0056 ] The animal model may also be used to determine 
the appropriate concentration range and route of adminis 
tration . Such information can then be used to determine 
useful doses and routes for administration in humans . 
[ 0057 ] The precise effective dose for a human subject will 
depend upon the severity of the disease state , general health 
of the subject , age , weight , and gender of the subject , diet , 
time and frequency of administration , reaction sensitivities , 
and tolerance / response to therapy . This amount can be 
determined by routine experimentation and is within the 
judgement of the clinician . 
[ 0058 ] What is meant by salt of acetyl L - carnitine or 
propionyl L - carnitine , is any salt with an acid that does not 
give rise to toxic or side effects . 
[ 0059 ] Non - limiting examples of such salts are : chloride , 
bromide , orotate , aspartate , acid aspartate , acid citrate , mag 
nesium citrate , phosphate , acid phosphate , fumarate and acid 
fumarate , magnesium fumarate , lactate , maleate and acid 
maleate , oxalate , acid oxalate , pamoate , acid pamoate , sul 
phate , acid sulphate , glucose phosphate , tartrate and acid 
tartrate , glycerophosphate , mucate , magnesium tartrate , 
2 - amino - ethanesulphonate , magnesium 2 - amino - ethanesul 
phonate , methanesulphonate , choline tartrate , trichloroac 
etate , and trifluoroacetate . 
[ 0060 ] A list of FDA - approved pharmaceutically accept 
able salts is given in the publication Int . J. of Pharm . 33 
( 1986 ) , 201-217 . 
[ 0061 ] Acetyl L - carnitine or propionyl L - carnitine are 
known compounds and their preparation process is 
described in U.S. Pat . No. 4,254,053 . Their procurements 
therefore is very easy , inasmuch as these products have been 
on the market now for a long time and are of a grade suitable 
for human administration . 
[ 0062 ] As shown in the experimental part reported in the 
following , the neurogenic activity of acetyl L - carnitine or 
propionyl L - carnitine according to the present invention is 
not correlated to their neuroprotective activity . 
[ 0063 ] In fact , at the concentrations that induced neuro 
genesis acetyl L - carnitine and propionyl L - carnitine did not 
reduce the percentage of apoptotic nuclei or the activity of 
the LDH enzyme , an index of necrosis . 
[ 0064 ] The following non limiting examples further illus 
trate the invention . 
EXAMPLE 1 
In Vitro ALC Modulates Neuronal Differentiation 
Of Adult Neural Progenitors Taken From the 
Mouse Hippocampus 
Introduction 
[ 0065 ] Complex set of events related to cell proliferation , 
differentiation , migration and survival that characterize adult 
neurogenesis starting from neural stem cells takes place 
even during adulthood . These events take place principally 
in two separate regions of the brain : the subgranular zone in 
the fascia dentata hippocampi ( SubGranular Zone , SGZ ) and 
the subventricular zone in the wall of the lateral ventricle 
( SubVentricular Zone , SVZ ) , where there is believed to be a 
favourable microenvironment ( niche ) that enables the stem 
cell to survive and divide periodically and asymmetrically 
giving rise to rapidly dividing progenitors some of which 
move towards neuronal differentiation . 
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MATERIALS AND METHODS were conducted on at least five cell preparations , with each 
experimental point in triplicate . 
Assessment and Cell Survival 
Animals and Preparation Of Hippocampal 
Neurospheres In Culture 
[ 0066 ] The adult stem cells from the mouse hippocampus 
were prepared and maintained in culture in the form of 
neurospheres as described previously in Denis - Donini S. et 
al . J. Neuroscience , 2008. In particular , male CD1mice aged 
3-5 months were used , in accordance with the animal 
experimentation laws . 
[ 0071 ] After differentiation in the presence of ALC , a 
vehicle or reference drugs , the medium was collected and 
the activity of the LDH enzyme was determined using the 
Cytotoxicity Detection Kit LDH ( Roche Applied Science ) , 
following the manufacturer's instructions , to quantify death 
due to necrosis . In parallel , to assess also apoptotic death , 
after fixation , the cell nuclei were marked with 0.8 ng / ml 
Hoechst ( Sigma - Aldrich ) diluted in PBS . The apoptic nuclei 
were counted by an operator ( blind to the nature of the 
treatment undergone by the cells ) using an ECLIPSE E600 
fluorescence microscope ( NIKON , Calenzano , Italy ) with a 
60x lens . All experiments were conducted on at least five 
cell preparations , with each experimental point in triplicate . 
Proliferation Of Stem Cells / Adult Neural 
Progenitors 
[ 0067 ] Neurospheres with passages of between 4-12 were 
dissociated and plated at a density of 1x10 cells / ml in a 
96 - well plate in ALC ( 0.1-2 mM ) at different concentrations 
or a vehicle . After 24 , 48 , 72 and 96 hours , the cells were 
processed to measure the amount of cell ATP present using 
the CellTiter - GlowTM Luminescent kit ( Promega ) . 
Results 
Differentiation Of Stem Cells / Adult Neural 
Progenitors 
[ 0068 ] For differentiation , the cells derived from the hip 
pocampal neurospheres with passages of between 4-12 were 
dissociated and plated on Lab - Tek 8 - well permanox cham 
ber slides ( Nunc , Wiesbaden , Germany ) previously coated 
with mouse laminin ( 2.5 ug / cm² Sigma ) at a density of about 
40,000 cells / cm² . The composition of the differentiation 
medium was : Neurobasal - A , supplement B27 , glutamine 2 
mM , 100 U / 100 ug / ml penicillin / streptomycin . ALC ( 0.1-2 
mM ) or a vehicle was added to the medium . After 24 hours 
the cells were washed and fixed in 4 % paraformaldehyde for 
20 min for subsequent analysis using immunofluorescence . 
Analysis Using Immunofluorescence 
[ 0069 ] The cells fixed after differentiation in the presence 
of ALC , a vehicle or reference drugs were washed three 
times in PBS and permeabilized by incubation for 5 min , at 
room temperature with PBS supplemented with 0.48 % ( vol / 
vol ) Triton X - 100 ( Sigma ) . Subsequently the cells were 
incubated with the following primary antibodies : anti - nestin 
mouse monoclonal antibody , 1 : 1200 , Abcam , Cambridge , 
Mass . ) ; anti - MAP - 2 ( rabbit polyclonal antibody , 1 : 600 , 
Chemicon ) . The cells were incubated in the primary anti 
body for 150 min at room temperature in a solution con 
taining 8 % ( vol / vol ) of goat serum . The secondary antibod 
ies used were : Alexa Fluor 594 - conjugated donkey anti 
mouse antibody ( 1 : 1400 , Molecular Probes ) , Alexa Fluor 
488 - conjugated donkey anti - rabbit ( 1 : 1 600 , Molecular 
Probes ) , in a solution containing 16 % ( vol / vol ) of donkey 
serum . The nuclei were then counterstained with Draq5 
( 1 : 2000 , Alexis Biochemicals ) prepared in PBS . The slides 
were assembled using Fluorescent Mounting Medium ( Da 
koCytomation , Glostrup ) . 
[ 0070 ] In each experiment , the cells of at least 5 fields / well 
( corresponding to about 150 cells ) , were quantified if posi 
tive to one or more phenotypical markers used to distinguish 
between them : undifferentiated stem progenitor cells , imma 
ture neurons , mature neurons . The cells were counted by an 
operator ( blind to the nature of the treatment undergone by 
the cells ) using an ECLIPSE E600 fluorescence microscope 
( NIKON , Calenzano , Italy ) with a 60x lens . All experiments 
[ 0072 ] In this study the microtubule associated protein 2 
( MAP2 ) was used as a neuro ur n - specific marker . MAP - 2 is the 
major microtubule - associated protein of brain tissue . There 
is some indication that MAP2 is expressed at higher levels 
in some types of neurons than in others . MAP2 is known to 
promote microtubule assembly and to form side - arms on 
microtubules , which is an essential step in neurogenesis . It 
also interacts with neurofilaments , actin , and other elements 
of the cytoskeleton . 
[ 0073 ] In adult neurospheres from the mouse hippocam 
pus compared to valproic acid ( VPA ) , a positive neurogen 
esis modulator , it has been demonstrated that ALC has a 
dose - dependent strengthening effect on the differentiation of 
stem cells / adult progenitors to mature and immature neurons 
( FIG . 1 ) . In fact , ALC has a marked concentration - depen 
dent hippocampal neurogenic activity as demonstrated by 
the increase in the percentage of MAP - 2 positive cells in 
culture . 
[ 0074 ] The hippocampal neurogenic activity of ALC was 
also evaluated by MAP - 2 staining ( green ) in cultured neu 
rons by immunofluorescence staining . Nuclei were stained 
with Draq5 ( FIG . 2 ) . 
[ 0075 ] The neurogenic activity of ALC is not correlated to 
neuroprotective activity . In fact , at the concentrations that 
induced neurogenesis , ALC ( 100 UM ; 300uM or 1 mM ) did 
not reduce the percentage of apoptotic nuclei ( FIG . 3 ) or 
even reduce the activity of the LDH enzyme , an index of 
necrosis , in the culture medium ( FIG . 4 ) . 
[ 0076 ) Nestin , an intermediate filament protein predomi 
nantly expressed by neural stem cells was also used as a 
specific marker . In fact , only nestin - positive cells form 
spheres when placed in the culture conditions used for 
neural stem cells . In particular , mature neurons are positive 
for MAP2 and negative for nestin , immature neurons are 
positive for both MAP2 and nestin , stem / progenitor cells are 
negative for MAP2 and positive for nestin , and progenitor 
cells are negative for both MAP2 and nestin ( FIG . 5 ) . 
[ 0077 ] Treatment with ALC increased the number of 
mature neurons in a concentration - dependent manner , as 
well as the number of immature neurons ; ALC had no effect 
on the number of stem / progenitor cells and decreased the 
number of progenitor cells . 
[ 0078 ] The experimental data reported in FIGS . 1-6 show 
that ALC and PLC are able to promote the neuronal differ 
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entiation of adult mouse hippocampal neural progenitors . In 
particular , ALC increases the number of both mature neu 
rons and immature neurons ; reduces the number of a sub 
population of undifferentiated stem / neural progenitors ; and 
carries out an activity that is not due to its neuroprotective 
effect . 
EXAMPLE 2 
In Vitro Comparison Of ALC PLC and LC On 
Modulation Of Neuronal Differentiation Of Adult 
Neural Progenitors Taken from the Mouse 
Hippocampus 
[ 0079 ] In example 2 , by using the same experimental 
procedures as for example 1 , the activity of ALC ( 1 mM ) as 
a modulator of adult hippocampal neurogenesis in an in vitro 
model of adult neural progenitor cells has been compared to 
that of propionyl - L - carnitine ( PLC ) ( 0.3-1 mM ) and L - car 
nitine ( LC ) ( 0.3-1 mM ) . As reported in FIG . 6 , compared to 
ALC , PLC appeared to be a less potent activator of NPC 
neuronal differentiation . In fact PLC increased the number 
of both mature neurons and immature neurons and reduced 
the number of a subpopulation of undifferentiated stem / 
neural progenitors , although in a lesser extent compared to 
ALC . On the contrary , LC had no effect . Moreover the 
results demonstrated that ALC and PLC effects on NPC 
differentiation were not due to neuroprotective effects on 
newly generated immature or mature neurons . 
1. - 15 . ( canceled ) 
16. A method for increasing neurogenesis , said method 
consisting of administering to a patient in need thereof a 
dose of an active agent , said active agent consisting of acetyl 
L - carnitine or a salt thereof , said acetyl L - carnitine or said 
salt thereof being suitable for preventing a central nervous 
system disorder selected from the group consisting of Shy 
Drager syndrome , Lewy body disease and spinal ischemia , 
wherein said dose corresponds to 0.1 to 4.00 g / day admin 
istered in a single or multiple doses . 
17. The method of claim 16 , wherein the salt of acetyl 
L - carnitine is selected from the group consisting of : chlo 
ride , bromide , orotate , aspartate , acid aspartate , acid citrate , 
magnesium citrate , phosphate , acid phosphate , fumarate and 
acid fumarate , magnesium fumarate , lactate , maleate and 
acid maleate , oxalate , acid oxalate , pamoate , acid pamoate , 
sulphate , acid sulphate , glucose phosphate , tartrate and acid 
tartrate , glycerophosphate , mucate , magnesium tartrate , 
2 - amino - ethanesulphonate , magnesium 2 - amino - ethanesul 
phonate , methanesulphonate , choline tartrate , trichloroac 
etate , and trifluoroacetate . 
18. The method of claim 16 , wherein the acetyl L - carni 
tine is administered in a dose of 1 to 2.00 g / day , in a single 
or multiple doses . 
19. The method of claim 16 , wherein the acetyl L - carni 
tine is administered in a dose of 1.5 g / day , in a single or 
multiple doses . 
20. The method of claim 16 , wherein the acetyl L - carni 
tine is administered by oral , subcutaneous , transdermal , 
intraperitoneal , intramuscular , in vein , intracerebroventricu 
lar , intraparenchymal , intrathecal , intracranial , buccal , 
mucosal , nasal , pulmonary , rectal administration or by a 
liposome delivery system . 
